Name (Synonyms) | Correlation | |
---|---|---|
drug689 | Recombinase aided amplification (RAA) assay Wiki | 1.00 |
drug616 | Placebo Wiki | 0.10 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg BID) to treat hospitalized patients with moderate COVID-19.
Description: PCR will be done to evaluate the change in viral load
Measure: Viral load Time: day 1, 4, 7, 14 and 21Description: Time to wean off oxygen supplementation
Measure: Evolution of acute respiratory syndrome Time: 21 daysDescription: WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)
Measure: Change in Clinical Condition Time: 21 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality within 21-days Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Need of mechanical ventilation Time: 21 days